LONDON, May 5, 2015 /PRNewswire/ --
- No one has covered
cath labs in India like us:
ABMRG
- Primary research
covering 700 angioplasty centres in 150 cities
- Comparative
analysis among states & regions; hospital chains; govt. &
pvt. hospitals
http://www.abmrg.com/India-Coronary-Stent-and-Angioplasty-Market-Through-2020-Cath-lab-level-Information---City-State-and-National-.html
The coronary stent market in
India, which comprises Drug
Eluting Stent (DES), Bare Metal Stent (BMS) and Bio-Absorbable
Stent (BVS), was valued above $400
million in 2012. DES accounts for bulk of sales in
India. The bio-absorbable stent
ABSORB has garnered a considerable traction despite its high cost
compared with the other available DES. The key players operating in
the segment are Alvimedica, Abbott Vascular, a division of Abbott
Laboratories (NYSE : ABT), Boston Scientific (NYSE : BSX, LSE :
BSX), Biosensors Inc., Biotronik, JW Medical, Medtronic, Inc. (NYSE
: MDT), Meril Life Sciences, MicroPort Scientific Corporation (HKG:
0853), Sahajanand Medical Technologies and Translumina
Therapeutics.
(Photo:
http://photos.prnewswire.com/prnh/20150505/743296)
(Logo:
http://photos.prnewswire.com/prnh/20140502/685460)
The market has grown impressively
supported by a rise in coronary angioplasties which has resulted
from a surge in cardiovascular diseases (CVDs), augmented
healthcare spending as well as an increase in number of
interventional cardiologists and cath labs in government and
private hospitals, including individual cath lab centres run by
interventional cardiologists as well as new corporate
hospitals.
The demand has surged as central and
state governments capped reimbursement rates which enhanced
affordability resulting in an increase in volume. The decrease in
reimbursement rates has given an edge to Indian, Asian and some of
the Europe-based mid-sized MNCs
which sell stents at almost half the price of those sold by US
companies.
"In the US, the stents market has
slumped significantly due to negative results from clinical studies
suggesting that one-third of stent implants are unnecessary.
However, in India these studies
have not made an impact as most Indian cardiologists do not seem to
have taken these clinical outcomes seriously," said Manoj Jiandani, CEO, ABMRG.
'India Coronary Stent and Angioplasty
Market Through 2020 (Cath Lab Level Information-City, State and
National)', is a market report published recently by ABMRG. It
reviews historical trends and forecasts (between 2007 and 2020),
annualised sales, market size (value and units), market growth,
pricing, competitive landscape and market share.
The research report covers 700 cath
labs across the country. It analyses angioplasty procedures' (PCI
and PTCA) data for the country with a detailed analysis at
national, state, district, city and hospital levels. It provides
PCI data of 550 hospitals from more than 150 cities. "No one has
covered cath labs in India like
us," Jiandani said.
The report offers a proprietary
cross-category comparison for products and geographies for the
historical and forecast period. It also lists strategic
developments in the global industry over the last two years,
including M&As, partnerships, clinical studies, pipelines
(R&D), product approvals and launches, recalls and litigations,
market dynamics, market drivers and restraints.
Why one should buy this
report
The report can be instrumental in
formulating strategic decisions to:
-
Make a regional strategy based on
regional landscape and market characteristics.
-
Capitalise on opportunities in
high-growth angioplasty regions/markets.
-
Plan capital investments based on the
forecast for high angioplasty markets.
-
Prepare strategic presentations for
the management, investors and shareholders.
Other strategic market
reports:
http://www.abmrg.com/Global-Coronary-Stent-Market-Outlook-Through-2019.html
http://www.abmrg.com/EU-7-Coronary-Stents-Market-Outlook-Through-2019.html
http://www.abmrg.com/European-Interventional-Cardiology-Market-through-2020.html
About ABMRG
ABMRG (Ace Business and Market Research
Group) is a research and consulting firm focused on life sciences.
It offers comprehensive research and analytical studies targeting
various therapeutic sectors and its market dynamics, vital trends,
business strategies and clinical pipeline. Its cutting edge reports
empower companies to make smarter, effective and faster strategic
decisions for business growth.
Contact:
Ankit Jian
sales@abmrg.com ; 19@abmrg.com
+91-8238155239; +91-261-2216406